Search Results - "Moran, Jenna"

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation by Fathi, Amir T., Blonquist, Traci M., Hernandez, Daniela, Amrein, Philip C., Ballen, Karen K., McMasters, Malgorzata, Avigan, David E., Joyce, Robin, Logan, Emma K., Hobbs, Gabriela, Brunner, Andrew M., Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Behnan, Tanya, Foster, Julia, Bergeron, Meghan K., Moran, Jenna A., Ramos, Aura Y., Som, Tina T., Rae, Jessica, Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Levis, Mark J.

“…BACKGROUND Cabozantinib, a tyrosine kinase inhibitor of FMS‐like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is…”
Get full text

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia by Narayan, Rupa, Blonquist, Traci M., Emadi, Ashkan, Hasserjian, Robert P., Burke, Meghan, Lescinskas, Christopher, Neuberg, Donna S., Brunner, Andrew M., Hobbs, Gabriela, Hock, Hanno, McAfee, Steven L., Chen, Yi‐Bin, Attar, Eyal, Graubert, Timothy A., Bertoli, Christina, Moran, Jenna A., Bergeron, Meghan K., Foster, Julia E., Ramos, Aura Y., Som, Tina T., Vartanian, Megan K., Story, Jennifer L., McGregor, Kristin, Macrae, Molly, Behnan, Tanya, Wey, Margaret C., Rae, Jessica, Preffer, Frederic I., Lesho, Patricia, Duong, Vu H., Mann, Mason L., Ballen, Karen K., Connolly, Christine, Amrein, Philip C., Fathi, Amir T.

“…Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high…”
Get full text

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies by How, Joan, Ren, Siyang, Lombardi‐Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi‐Bin, Duda, Dan G., Hobbs, Gabriela S.

“…We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with…”
Get full text

Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype by Jalbut, Marla M, Sohani, Aliyah R, Cin, Paola Dal, Hasserjian, Robert P, Moran, Jenna A, Brunner, Andrew M, Fathi, Amir T

“…Abstract Klinefelter syndrome (KS), a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to…”
Get full text

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience by Miller, Kevin C., Lombardi Story, Jennifer, Foster, Julia, Moran, Jenna A., Fathi, Amir T., Hobbs, Gabriela S.

Get full text

Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh by Yeh, Albert C, Khan, Mohiuddin A, Harlow, Jason, Biswas, Akhil R, Akter, Mafruha, Ferdous, Jannatul, Ara, Tasneem, Islam, Manirul, Caron, Martin, Barron, Anne-Marie, Moran, Jenna, Brezina, Mark, Nazneen, Humayra, Kamruzzaman, Md, Saha, Anup, Marshall, Ariela, Afrose, Salma, Stowell, Christopher, Preffer, Frederic, Bangsberg, David, Goodman, Annekathryn, Attar, Eyal, McAfee, Steven, Spitzer, Thomas R, Dey, Bimalangshu R

“…Treatment of malignant and nonmalignant hematologic diseases with hematopoietic stem-cell transplantation (HSCT) was first described almost 60 years ago, and…”
Get full text

Building Specialized Nursing Practice Capacity in Bangladesh: An Educational Program to Prepare Nurses to Care for Oncology and Bone Marrow Transplant Patients in Dhaka, Bangladesh by Barron, Anne-Marie, Moran, Jenna, Nina, Shabnam Sultana, Harlow, Jason, Gyawali, Meena, Hossain, Farhad, Brezina, Mark, Callahan, Caroline, Curran, Judy, Danielson, Colleen, Fitzgerald, Ellen, Foster, Judy, Erhardt, Emily, Shaughnessy, Christine, Yeh, Albert C, Dey, Bimalangshu R

“…In 2012, the Minister of Health and other leaders in the Bangladesh government approached Massachusetts General Hospital to establish the country's first bone…”
Get full text

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia by Arslan, Shukaib, Zhang, Jianying, Dhakal, Prajwal, Moran, Jenna, Naidoo, Nuthana, Lombardi, Jennifer, Pullarkat, Vinod, Stein, Anthony S., Marcucci, Guido, Yaghmour, George, Bhatt, Vijaya R., Fathi, Amir T., Aldoss, Ibrahim

Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey G, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven, Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Get full text

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML) by Arslan, Shukaib, Zhang, Jianying, Dhakal, Prajwal, Moran, Jenna A., Naidoo, Nuthana, Lombardi Story, Jennifer, Pullarkat, Vinod A., Stein, Anthony S., Marcucci, Guido, Yaghmour, George, Bhatt, Vijaya R., Fathi, Amir T., Aldoss, Ibrahim

“…Introduction: Venetoclax (VEN) in combination with a hypomethylating agents (HMA) is associated with a high rate of composite remission (complete remission…”
Get full text

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML) by Fathi, Amir T., Perl, Alexander E., Levis, Mark, Smith, Catherine C., Brunner, Andrew M., Takahashi, Koichi, Amrein, Philip C., Hock, Hanno R., Hobbs, Gabriela S., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Daver, Naval, DiNardo, Courtney D.

“…Characterization of pathogenic alterations in acute myeloid leukemia (AML) has led to development of promising targeted therapies, including FLT3 (FLT3i) and…”
Get full text

Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults by Amrein, Philip, Ballen, Karen, Stevenson, Kristen, Brunner, Andrew, Hobbs, Gabriela, Hock, Hanno, McAfee, Steven, Moran, Jenna, Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGreggor, Kristin, Macrea, Molly, Burke, Meghan, Behnam, Tanya, Som, Tina, Ramos, Aura, Vartanian, Megan, Lombardi Story, Jennifer, Connolly, Christine, Blonquist, Traci, Neuberg, Donna, Fathi, Amir

“…We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic…”
Get full text

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Stevenson, Kristen E., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Graubert, Timothy A., Neuberg, Donna S., Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

“…Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged…”
Get full text

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies by How, Chi-Joan, Ren, Siyang, Lombardi Story, Jennifer, Bergeron, Meghan, Foster, Julia E., Amrein, Philip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno R., Moran, Jenna A., Narayan, Rupa, Neuberg, Donna S., Ramos, Aura Y., Som, Tina T., Vartanian, Megan, Chen, Yi-Bin, Hobbs, Gabriela S.

“…Angiogenesis is increasingly known to play a role in pathogenesis of hematologic malignancies, including myeloid neoplasms. Regorafenib is a multikinase…”
Get full text

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy by Venkataraman, Vinayak, Casey, Keagan S., Onozato, Maristela, Cin, Paola Dal, Nardi, Valentina, Amrein, Philip C., Bergeron, Meghan K., Brunner, Andrew M., Fathi, Amir T., Foster, Julia E., Moran, Jenna, Graubert, Timothy A., Hock, Hanno, Hunnewell, Chrisa, Frigault, Matthew J., McAfee, Steven, Hobbs, Gabriela S.

Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: Treatment of acute myeloid leukemia (AML) has remained largely unchanged for several decades despite the emergence of new agents. Long-term…”
Get full text

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia by Fathi, Amir T., Blonquist, Traci M., Emadi, Ashkan, Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Hasserjian, Robert P., Preffer, Frederic I., Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Lesho, Patricia, Duong, Vu H., Mann, Mason, Lescinskas, Christopher, Connolly, Christine, Neuberg, Donna S, Ballen, Karen K., Amrein, Philip C.

“…Background: Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) consisting of an antibody specific for human CD30, an anti-microtubule agent…”
Get full text

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia by Brunner, Andrew M., Blonquist, Traci M., DeAngelo, Daniel J., McMasters, Malgorzata, Winer, Eric S., Hobbs, Gabriela S., Amrein, Philip C., Hock, Hanno, Steensma, David P., Garcia, Jacqueline S., Luskin, Marlise R., Stone, Richard M., Ballen, Karen K., Rosenblatt, Jacalyn, Avigan, David E., McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Nelson, Nicole, Logan, Emma, Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A., Fathi, Amir T.

“…▪ Background: Aurora kinases play essential roles in regulating cell division, and increased expression has been noted in myelodysplastic syndromes (MDS) and…”
Get full text